Skip to Content

GG 705 (Ranitidine 150 mg)

Pill imprint GG 705 has been identified as Ranitidine hydrochloride 150 mg.

Ranitidine is used in the treatment of gerd; erosive esophagitis; duodenal ulcer; zollinger-ellison syndrome; eczema (and more), and belongs to the drug class H2 antagonists. There is no proven risk in humans during pregnancy. Ranitidine 150 mg is not a controlled substance under the Controlled Substance Act (CSA).

Ranitidine hydrochloride 150 mg GG 705  Front
Ranitidine hydrochloride 150 mg GG 705  Back
Ranitidine hydrochloride 150 mg GG 705
Ranitidine hydrochloride
GG 705
150 mg
8.00 mm
Rx and/or OTC
Drug Class:
H2 antagonists
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Sandoz Pharmaceuticals Inc.
National Drug Code (NDC):
Inactive Ingredients:
D&C Red No. 30
hydroxypropyl cellulose
hypromellose 2910 (3 mPa.s)
magnesium stearate
microcrystalline cellulose
sodium starch glycolate type A potato
titanium dioxide
triethyl citrate
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
51079-0879 UDL Laboratories Inc
63739-0266 McKesson Packaging Services
66267-0188 Nucare Pharmaceuticals Inc (repackager)
57866-6930 Direct Dispensing Inc (repackager)
67544-0049 Prepak Systems Inc (repackager)
21695-0109 Rebel Distributors Corp (repackager)
23490-6249 Palmetto State Pharmaceuticals Inc (repackager)

Note: Inactive ingredients may vary.

View Details Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.